toxylact

The first professional lActological database in the word

Morphine combinations (ATC A07DA52) are opioid‑based antipropulsives that combine morphine with intestinal adsorbents or antispasmodics to reduce gastrointestinal motility and secretions in acute diarrhea, but because morphine passes readily into breast milk and can depress infant respiration and consciousness, these products are generally contraindicated or strongly discouraged during breastfeeding.atcddd.fhi+5

ATC A07DA52 overview

ATC code A07DA52 “Morphine, combinations” belongs to the antipropulsives subgroup A07DA within A07 antidiarrheals and intestinal anti‑infective/anti‑inflammatory agents. This 5th‑level code covers combinations in which morphine is used as an intestinal motility inhibitor together with components such as aluminium hydroxide, belladonna alkaloids, kaolin or antiflatulents for treatment of acute diarrhea; morphine combinations for pain control are classified separately in N02AA51.atcddd.fhi+3

Pharmacology and mechanism

Morphine is a prototypical opioid analgesic that also exerts strong antidiarrheal effects by activating μ‑opioid receptors in the enteric nervous system, reducing propulsive peristalsis and increasing fluid absorption. In A07DA52 formulations, co‑components such as kaolin or aluminium hydroxide provide additional adsorbent and mucosa‑protective effects, while belladonna alkaloids contribute anticholinergic actions that further decrease intestinal secretions and motility.ncbi.nlm.nih+5

Therapeutic indications

Morphine combinations in this class are indicated for short‑term symptomatic treatment of acute severe diarrhea in adults when other antidiarrheals are insufficient, as reflected by DDDs based on acute diarrhea therapy. Historically, such combinations (for example Tanagel‑type products) have been used as prescription‑only agents for refractory diarrheal states, not for routine self‑limited episodes.farmacotherapeutischkompas+2

Pharmacokinetics relevant to lactation

Morphine is well absorbed after oral administration, although oral bioavailability is variable; it is widely distributed and crosses biological membranes, including into breast milk. Clinical experience and pharmacokinetic data indicate that opium‑derived alkaloids (including morphine) can appear in milk at concentrations higher than maternal plasma, implying efficient transfer and significant potential exposure for breastfed infants.ncbi.nlm.nih+3

Maternal safety and adverse effects

In addition to the antidiarrheal benefit, morphine‑containing combinations carry typical opioid adverse effects such as constipation, nausea, vomiting, sedation, dizziness, and risk of dependence with repeated use. Belladonna or other anticholinergic co‑components add risks of dry mouth, blurred vision, tachycardia, urinary retention, and, in overdose, confusion or delirium, which can be particularly problematic in older or comorbid adults.atcddd.fhi+3

Lactation safety assessment

National formularies and lactation‑focused resources advise avoiding opium and morphine‑containing antidiarrheal products in breastfeeding, noting that opium/morphine can be present in breast milk in higher concentrations than in maternal plasma. Antidiarrheal guidance for breastfeeding mothers explicitly recommends against opium‑ or morphine‑based antipropulsives due to the risk of infant opioid toxicity and the availability of better‑characterized, safer alternatives such as loperamide.who+4

Potential effects on the breastfed infant

The primary risks to the breastfed infant from maternal use of A07DA52 morphine combinations are opioid‑induced central nervous system and respiratory depression—manifesting as excessive sleepiness, poor feeding, hypotonia, and, in severe cases, apnea. The presence of belladonna alkaloids or other anticholinergics may additionally lead to infant tachycardia, flushed skin, dry mucous membranes, or urinary retention, particularly in neonates and preterm infants who are highly susceptible to these effects.ncbi.nlm.nih+4

Practical recommendations in breastfeeding

For breastfeeding women with acute diarrhea, best practice is to continue breastfeeding, use oral rehydration salts to correct fluid and electrolyte losses, and, when pharmacologic symptom control is needed, select loperamide as the antipropulsive of choice given its minimal milk transfer and negligible infant bioavailability. Morphine‑containing antipropulsives (A07DA52) should not be used during breastfeeding; if a mother is already on morphine combinations for refractory diarrhea, urgent reassessment is required, with consideration of switching to safer regimens and close monitoring of the infant—or temporary interruption of breastfeeding—depending on exposure and infant condition.ncbi.nlm.nih+6

Role within antipropulsives

Within the antipropulsives class, morphine combinations are potent motility inhibitors but have a substantially less favorable toxico‑lactological profile than peripherally acting agents such as loperamide and its oxide. From a lactation‑safety standpoint they are relegated to non‑lactating adults with severe or chronic refractory diarrhea, while breastfeeding‑compatible antidiarrheal strategies rely on oral rehydration, low‑risk antipropulsives, and judicious use of other supportive measures.ncbi.nlm.nih+5

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.